When is a one-year follow-up DXA recommended?

• A. After fracture
• B. After 2 years
• C. For patients on chronic glucocorticoid therapy
• D. For all postmenopausal

Answer: (C)

The main concept is that bone density monitoring is most critical when a patient has a strong cause of rapid bone loss, specifically chronic glucocorticoid use. Glucocorticoids accelerate bone resorption and suppress bone formation, causing significant BMD decline early in therapy. Because this loss can occur quickly, a follow-up DXA about one year after starting chronic glucocorticoids helps quantify how much BMD has changed and whether preventive measures or osteoporosis treatment are working, guiding further management.

Context helps: baseline BMD is ideally established before or soon after starting glucocorticoids, and repeating at around 12 months captures the early trajectory of bone loss. If the BMD has declined or the fracture risk remains high, clinicians can intensify therapy (such as adding anti-resorptives, ensuring vitamin D and calcium sufficiency, and addressing risk factors).

Other scenarios aren’t as standardized for a one-year check. After a fracture, testing and treatment decisions are based on fracture risk and existing guidelines, but the exact one-year timing isn’t the universal rule. Waiting two years isn’t typical for monitoring GC-induced bone loss, and not every postmenopausal patient requires a one-year follow-up DXA unless there are specific risk factors like ongoing glucocorticoid therapy.